Involvement of nitric oxide synthase in matrix metalloproteinase-9- and/or urokinase plasminogen activator receptor-mediated glioma cell migration

BMC Cancer

Krishna Kumar Veeravalli²  Jasti S Rao¹  Eleonora Zakharian²  Chandramu Chetty²  Azeem A Rehman²  Kiran Kumar Velpula²  Shivani Ponnala²  Bharath Chelluboina²  Thompson Zhuang² 

[1]Department of Neurosurgery, University of Illinois College of Medicine at Peoria, Peoria, IL 61605, USA

[2]Department of Cancer Biology and Pharmacology, University of Illinois College of Medicine at Peoria, One Illini Drive, Peoria, IL 61605, USA

关键词: Knockdown;    Integrin;    Migration;    Nitric oxide;    Glioma;   

Others  :  859203
DOI  :  10.1186/1471-2407-13-590

 received in 2013-07-12, accepted in 2013-12-06,  发布年份 2013

【 摘 要 】

Background

Src tyrosine kinase activates inducible nitric oxide synthase (iNOS) and, in turn, nitric oxide production as a means to transduce cell migration. Src tyrosine kinase plays a key proximal role to control α9β1 signaling. Our recent studies have clearly demonstrated the role of α9β1 integrin in matrix metalloproteinase-9 (MMP-9) and/or urokinase plasminogen activator receptor (uPAR)-mediated glioma cell migration. In the present study, we evaluated the involvement of α9β1 integrin-iNOS pathway in MMP-9- and/or uPAR-mediated glioma cell migration.

Methods

MMP-9 and uPAR shRNAs and overexpressing plasmids were used to downregulate and upregulate these molecules, respectively in U251 glioma cells and 5310 glioma xenograft cells. The effect of treatments on migration and invasion potential of these glioma cells were assessed by spheroid migration, wound healing, and Matrigel invasion assays. In order to attain the other objectives we also performed immunocytochemical, immunohistochemical, RT-PCR, Western blot and fluorescence-activated cell sorting (FACS) analysis.

Results

Immunohistochemical analysis revealed the prominent association of iNOS with glioblastoma multiforme (GBM). Immunofluorescence analysis showed prominent expression of iNOS in glioma cells. MMP-9 and/or uPAR knockdown by respective shRNAs reduced iNOS expression in these glioma cells. RT-PCR analysis revealed elevated iNOS mRNA expression in either MMP-9 or uPAR overexpressed glioma cells. The migration potential of MMP-9- and/or uPAR-overexpressed U251 glioma cells was significantly inhibited after treatment with L-NAME, an inhibitor of iNOS. Similarly, a significant inhibition of the invasion potential of the control or MMP-9/uPAR-overexpressed glioma cells was noticed after L-NAME treatment. A prominent reduction of iNOS expression was observed in the tumor regions of nude mice brains, which were injected with 5310 glioma cells, after MMP-9 and/or uPAR knockdown. Protein expressions of cSrc, phosphoSrc and p130Cas were reduced with simultaneous knockdown of both MMP-9 and uPAR.

Conclusions

Taken together, our results from the present and earlier studies clearly demonstrate that α9β1 integrin-mediated cell migration utilizes the iNOS pathway, and inhibition of the migratory potential of glioma cells by simultaneous knockdown of MMP-9 and uPAR could be attributed to the reduced α9β1 integrin and iNOS levels.

【 授权许可】

   
2013 Zhuang et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Giese A, Westphal M: Glioma invasion in the central nervous system. Neurosurgery 1996, 39:235-250.
• [2]Ramos-DeSimone N, Hahn-Dantona E, Sipley J, Nagase H, French DL, Quigley JP: Activation of matrix metalloproteinase-9 (MMP-9) via a converging plasmin/stromelysin-1 cascade enhances tumor cell invasion. J Biol Chem 1999, 274:13066-13076.
• [3]Kallakury BV, Karikehalli S, Haholu A, Sheehan CE, Azumi N, Ross JS: Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma. Clin Cancer Res 2001, 7:3113-3119.
• [4]Kachra Z, Beaulieu E, Delbecchi L, Mousseau N, Berthelet F, Moumdjian R, del Maestro R, Beliveau R: Expression of matrix metalloproteinases and their inhibitors in human brain tumors. Clin Exp Metastasis 1999, 17:555-566.
• [5]Raithatha SA, Muzik H, Muzik H, Rewcastle NB, Johnston RN, Edwards DR, Forsyth PA: Localization of gelatinase-A and gelatinase-B mRNA and protein in human gliomas. Neurooncol 2000, 2:145-150.
• [6]Rooprai HK, van Meter T, Rucklidge GJ, Hudson L, Everall IP, Pilkington GJ: Comparative analysis of matrix metalloproteinases by immunocytochemistry, immunohistochemistry and zymography in human primary brain tumours. Int J Oncol 1998, 13:1153-1157.
• [7]Rao JS, Steck PA, Mohanam S, Stetler-Stevenson WG, Liotta LA, Sawaya R: Elevated levels of M(r) 92,000 type IV collagenase in human brain tumors. Cancer Res 1993, 53:2208-2211.
• [8]Veeravalli KK, Chetty C, Ponnala S, Gondi CS, Lakka SS, Fassett D, Klopfenstein JD, Dinh DH, Gujrati M, Rao JS: MMP-9, uPAR and cathepsin B silencing downregulate integrins in human glioma xenograft cells in vitro and in vivo in nude mice. PLoS One 2010, 5:e11583.
• [9]Veeravalli KK, Rao JS: MMP-9 and uPAR regulated glioma cell migration. Cell Adh Migr 2012, 6:509-512.
• [10]Gupta SK, Vlahakis NE: Integrin alpha9beta1: Unique signaling pathways reveal diverse biological roles. Cell Adh Migr 2010, 4:194-198.
• [11]Jadeski LC, Chakraborty C, Lala PK: Nitric oxide-mediated promotion of mammary tumour cell migration requires sequential activation of nitric oxide synthase, guanylate cyclase and mitogen-activated protein kinase. Int J Cancer 2003, 106:496-504.
• [12]Ridnour LA, Windhausen AN, Isenberg JS, Yeung N, Thomas DD, Vitek MP, Roberts DD, Wink DA: Nitric oxide regulates matrix metalloproteinase-9 activity by guanylyl-cyclase-dependent and -independent pathways. Proc Natl Acad Sci USA 2007, 104:16898-16903.
• [13]Kostourou V, Cartwright JE, Johnstone AP, Boult JK, Cullis ER, Whitley G, Robinson SP: The role of tumour-derived iNOS in tumour progression and angiogenesis. Br J Cancer 2011, 104:83-90.
• [14]Franchi A, Santucci M, Masini E, Sardi I, Paglierani M, Gallo O: Expression of matrix metalloproteinase 1, matrix metalloproteinase 2, and matrix metalloproteinase 9 in carcinoma of the head and neck. Cancer 2002, 95:1902-1910.
• [15]Lakka SS, Gondi CS, Dinh DH, Olivero WC, Gujrati M, Rao VH, Sioka C, Rao JS: Specific interference of uPAR and MMP-9 gene expression induced by double-stranded RNA results in decreased invasion, tumor growth and angiogenesis in gliomas. J Biol Chem 2005, 280:21882-21892.
• [16]Giannini C, Sarkaria JN, Saito A, Uhm JH, Galanis E, Carlson BL, Schroeder MA, James CD: Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme. Neurooncol 2005, 7:164-176.
• [17]Pullen NA, Fillmore HL: Induction of matrix metalloproteinase-1 and glioma cell motility by nitric oxide. J Neurooncol 2010, 96:201-209.
• [18]Fukumura D, Kashiwagi S, Jain RK: The role of nitric oxide in tumour progression. Nat Rev Cancer 2006, 6:521-534.
• [19]Williams EL, Djamgoz MB: Nitric oxide and metastatic cell behaviour. Bioessays 2005, 27:1228-1238.
• [20]Eyler CE, Wu Q, Yan K, MacSwords JM, Chandler-Militello D, Misuraca KL, Lathia JD, Forrester MT, Lee J, Stamler JS, Goldman SA, Bredel M, McLendon RE, Sloan AE, Hjelmeland AB, Rich JN: Glioma stem cell proliferation and tumor growth are promoted by nitric oxide synthase-2. Cell 2011, 146:53-66.
• [21]Babykutty S, Suboj P, Srinivas P, Nair AS, Chandramohan K, Gopala S: Insidious role of nitric oxide in migration/invasion of colon cancer cells by upregulating MMP-2/9 via activation of cGMP-PKG-ERK signaling pathways. Clin Exp Metastasis 2012, 29:471-492.
• [22]Chetty C, Lakka SS, Bhoopathi P, Gondi CS, Veeravalli KK, Fassett D, Klopfenstein JD, Dinh DH, Gujrati M, Rao JS: Urokinase plasminogen activator receptor and/or matrix metalloproteinase-9 inhibition induces apoptosis signaling through lipid rafts in glioblastoma xenograft cells. Mol Cancer Ther 2010, 9:2605-2617.
• [23]Veeravalli KK, Ponnala S, Chetty C, Tsung AJ, Gujrati M, Rao JS: Integrin alpha9beta1-mediated cell migration in glioblastoma via SSAT and Kir4.2 potassium channel pathway. Cell Signal 2012, 24:272-281.
• [24]Young BA, Taooka Y, Liu S, Askins KJ, Yokosaki Y, Thomas SM, Sheppard D: The cytoplasmic domain of the integrin alpha9 subunit requires the adaptor protein paxillin to inhibit cell spreading but promotes cell migration in a paxillin-independent manner. Mol Biol Cell 2001, 12:3214-3225.
• [25]Gupta SK, Vlahakis NE: Integrin alpha9beta1 mediates enhanced cell migration through nitric oxide synthase activity regulated by Src tyrosine kinase. J Cell Sci 2009, 122:2043-2054.
• [26]Jahani-Asl A, Bonni A: iNOS: a potential therapeutic target for malignant glioma. Curr Mol Med 2013, 13:1241-1249.
• [27]Chen TJ, Shen SC, Lin HY, Chien LL, Chen YC: Lipopolysaccharide enhancement of 12-o-tetradecanoylphorbol 13-acetate-mediated transformation in rat glioma C6, accompanied by induction of inducible nitric oxide synthase. Toxicol Lett 2004, 147:1-13.